Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Mar 2018 Status changed from not yet recruiting to recruiting.
- 19 Feb 2018 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2018.
- 27 Jun 2017 New trial record